Evidence map›Paper›PMID 28894085›Full record

ArticleNature communications2017

p190RhoGAP proteins contain pseudoGTPase domains.

Amy L Stiegler, Titus J Boggon

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Emerging functions of pseudoenzymes.The Biochemical journal · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Fixing the GAP: The role of RhoGAPs in cancer.European journal of cell biology · 2022
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. p190RhoGAPs, theCells · 2019
    Review
  14. Article
  15. PseudoGTPase domains in p190RhoGAP proteins: a mini-review.Biochemical Society transactions · 2018
    Review
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amy L StieglerDepartment of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Titus J BoggonDepartment of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA. titus.boggon@yale.edu.
Yale University · US

Funding

Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9M
Overall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3M
Structure-directed investigations into the regulation of Ste20 kinasesR01GM102262 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON · 2012 to 2025
$4.2M
Molecular assembly and regulation of the cerebral cavernous malformation complexR01NS085078 · NINDS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, CALDERWOOD, DAVID A · 2013 to 2017
$1.8M
The mechanism of Arg kinase activation by integrin B1R01GM100411 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, KOLESKE, ANTHONY J · 2012 to 2015
$1.3M
The function of MEKK3 interaction with CCM2R01GM114621 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, SU, BING · 2015 to 2018
$1.3M
Investigating cellular function and biochemical mechanism for STK24-CCM3 complexR01GM109487 · NIGMS · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON, WU, DIANQING · 2014 to 2017
$1.3M
Upgrade of a home source macromolecular X-ray diffraction system.S10OD018007 · OD · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON · 2014 to 2014
$460k
NCI NIH HHS P50 CA121974NIGMS NIH HHS P41 GM103403NIGMS NIH HHS R01 GM100411NIGMS NIH HHS R01 GM102262NIGMS NIH HHS R01 GM109487NIGMS NIH HHS R01 GM114621NIH HHS S10 OD018007NINDS NIH HHS R01 NS085078
6 · The paper itself

Abstract

The two p190RhoGAP proteins, p190RhoGAP-A and -B, are key regulators of Rho GTPase signaling and are essential for actin cytoskeletal structure and contractility. Here we report the discovery of two evolutionarily conserved GTPase-like domains located in the 'middle domain', previously thought to be unstructured. Deletion of these domains reduces RhoGAP activity. Crystal structures, MANT-GTPγS binding, thermal denaturation, biochemical assays and sequence homology analysis all strongly support defects in nucleotide-binding activity. Analysis of p190RhoGAP proteins therefore indicates the presence of two previously unidentified domains which represent an emerging group of pseudoenzymes, the pseudoGTPases.A growing number of 'pseudoenzymes' with a regulatory role in signal transduction processes but without catalytic activity are being identified. Here, the authors identify two pseudoGTPase domains in p190RhoGAP, characterize them biochemically and structurally and show that they influence RhoGAP activity.

Indexed as

AnimalsChickensCrystallizationDrosophila melanogasterDrosophila ProteinsGTPase-Activating ProteinsGTP PhosphohydrolasesGuanine Nucleotide Exchange FactorsHumansPoriferaProtein DomainsProtein FoldingRatsRepressor ProteinsSequence HomologyARHGAP35 protein, humanArhgap35 protein, ratARHGAP5 protein, humanDrosophila ProteinsGTPase-Activating ProteinsGTP PhosphohydrolasesGuanine Nucleotide Exchange FactorsRepressor Proteins

Identifiers

PMID28894085
PMCPMC5593906
OpenAlexW2753321674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.